DexCom (DXCM) said Thursday the Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring System for people at least 18 years old with diabetes in the US.
The device features 15.5 days of wear and provides easier glucose management with fewer monthly sensors and lower monthly waste, the company said.
The company said it is working with its insulin pump partners to ensure the wearable's compatibility with automated insulin delivery systems upon launch, which is expected to take place in the US in H2.
DexCom shares were up 9.6% in premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.